139.76USD-1.71%Mkt Cap: 8.21B $P/E: —1d ago
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It off…
Indicators:|
Key Statistics
Company
Market Cap8.21B $
Enterprise Value8.03B $
Revenue (TTM)551.35M $
Gross Profit282.76M $
Net Income (TTM)-187.69M $
Revenue/Share9.583 USD
Last Price139.76 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINUS3773221029
Valuation
P/E (Trailing)—
P/E (Forward)315.04
PEG—
EV/EBITDA-181.57
EV/Revenue14.57
P/S14.89
P/B12.16
EPS (TTM)-3.30
EPS (Forward)0.44
52W Range
73.1689% of range148.11
52W High148.11 USD
52W Low73.16 USD
Profitability
Gross Margin55.72%
Oper. Margin-13.19%
EBITDA Margin-8.02%
Profit Margin-36.99%
ROE-28.60%
ROA-21.01%
Growth
Revenue Growth41.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.79M $
CapEx (TTM)24.27M $
FCF Margin1.10%
FCF Yield0.07%
Net Debt-170.82M $
Net Debt/EBITDA3.86
Balance Sheet
Debt/Equity0.16
Current Ratio5.43
Quick Ratio4.43
Book Value/Sh11.50 USD
Cash/Share4.713 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)157.50 USD
Upside (mean)+12.7%
Target Range138.00 USD – 170.00 USD
$138.00+12.7% to mean$170.00
# Analysts12
Ownership
Shares Out.58.73M
Float57.71M
Insiders3.63%
Institutions104.41%
Short Interest
Short Ratio3.1d
Short % Float8.62%
Short % Out.7.11%
Shares Short4.18M
Short (prev mo.)3.31M
Technical
SMA 50128.20 (+9.0%)
SMA 200109.22 (+28.0%)
Beta0.81
S&P 52W Chg20.05%
Avg Vol (30d)892.89K
Avg Vol (10d)968.71K
Technical Indicators
RSI (14)61.2
MACD4.6681
MACD Signal2.8357
MACD Hist.+1.8324
BB Upper147.71 USD
BB Middle128.97 USD
BB Lower110.24 USD
BB Width29.05%
ATR (14)5.976 USD
Vol Ratio (20d)1.18x